GlassScriptPhysician profile
Abelardo Martinez-Rumayor
NPI 1861528234
$13,972.49
in general payments reported to CMS, 2019-2025
29 companies · $957 in 2025
The $957 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $94.03 · 2021: $761 · 2022: $1,040 · 2023: $986 · 2024: $9,259 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,600 · Food and Beverage: $2,941 · Travel and Lodging: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,600.00 |
| Food and Beverage | $2,941.27 |
| Travel and Lodging | $1,660.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $7,517.24 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $1,637.30 | 2021-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $997.57 | 2020-2025 | |
| Medtronic, INC. | $733.93 | 2022-2024 | Symplicity G3, Thunder |
| Janssen Pharmaceuticals, INC | $478.04 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $467.25 | 2019-2025 | Watchman Access System, Cds - Mct/Cem Monitoring |
| Osprey Medical INC | $260.00 | 2019 | |
| Merck Sharp & Dohme LLC | $245.31 | 2021-2025 | Verquvo, Capvaxive |
| Teleflex LLC | $184.67 | 2019-2024 | Arrow, Trapliner |
| Penumbra, INC. | $157.27 | 2025 | Indigo System |
| Pfizer INC. | $144.91 | 2021-2025 | |
| Abbott Laboratories | $139.79 | 2019 | |
| Amarin Pharma, INC. | $135.84 | 2019-2023 | |
| Stryker Corporation | $130.98 | 2025 | Flowtriever |
| Philips North America LLC | $122.26 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $115.00 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $94.90 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $76.62 | 2019-2025 | Repatha |
| Actelion Pharmaceuticals US, INC. | $56.23 | 2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $49.74 | 2023 | Farxiga, Brilinta |
| Sanofi-Aventis U.S. LLC | $45.44 | 2023-2024 | |
| Edwards Lifesciences Corporation | $44.59 | 2023-2024 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.91 | 2024-2025 | Jardiance |
| Chiesi USA, INC. | $28.22 | 2020 | |
| Irhythm Technologies, INC. | $23.80 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.97 | 2019 | |
| Glaxosmithkline, LLC. | $17.91 | 2025 | Arexvy, Shingrix |
| Celonova Biosciences, INC. | $13.40 | 2020 | |
| Cvrx, INC. | $2.40 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abelardo Martinez-Rumayor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.